Stavros G. Vizirgianakis
Known title: DirectorCIK: 0001559834
Stavros G. Vizirgianakis's purchase track record
Stavros G. Vizirgianakis has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/7/2022 | XTNT | $1.09M | -11.3% | -12.7% | +12.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XTNT | ▲ Buy | Grant | 323,275 | $0 | 8/15/2026 | View on chart |
| APYX | ▲ Buy | Grant | 450,000 | $0 | 6/11/2026 | View on chart |
| XTNT | ▲ Buy | Grant | 553,797 | $0 | 11/15/2025 | View on chart |
| XTNT | ▲ Buy | Grant | 243,243 | $0 | 8/15/2024 | View on chart |
| XTNT | ▲ Buy | Grant | 505,405 | $0 | 8/15/2024 | View on chart |
| XTNT | ▲ Buy | Grant | 217,770 | $0 | 8/15/2023 | View on chart |
| XTNT | ▲ Buy | Grant | 144,639 | $0 | 11/15/2022 | View on chart |
| XTNT | ▲ Buy | Open Market | 2,264,861 | $1.1M | 10/7/2022 | View on chart |
| XTNT | ▲ Buy | Grant | 70,776 | $0 | 8/25/2022 | View on chart |
| BVS | ▲ Buy | Option Exercise | 965 | $0 | 6/16/2022 | View on chart |
| BVS | ▲ Buy | Grant | 2,780,923 | — | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Apyx Medical featured in cold plasma market growth report
Apyx Medical was named as a key player in a new report projecting the cold plasma market to grow from $3.32 billion in 2025 to $8.45 billion by 2032. This industry-level forecast highlights the long-term potential of the sector in which Apyx operates. The company's stock is currently trading below its average analyst target price, reflecting ongoing market uncertainty despite these broader industry trends.
Apyx Medical featured in cold plasma market growth report. Apyx Medical was named as a key player in a new report projecting the cold plasma market to grow from $3.32 billion in 2025 to $8.45 billion by 2032. This industry-level forecast highlights the long-term potential of the sector in which Apyx operates. The company's stock is currently trading below its average analyst target price, reflecting ongoing market uncertainty despite these broader industry trends.